UBS O'Connor’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.75M | Buy |
223,596
+122,808
| +122% | +$2.06M | 0.19% | 80 |
|
|
2025
Q1 | $1.55M | Sell |
100,788
-37,237
| -27% | -$572K | 0.05% | 135 |
|
|
2024
Q4 | $3.04M | Buy |
138,025
+58,893
| +74% | +$1.3M | 0.08% | 119 |
|
|
2024
Q3 | $1.43M | Buy |
79,132
+28,236
| +55% | +$509K | 0.04% | 228 |
|
|
2024
Q2 | $827K | Buy |
50,896
+6,000
| +13% | +$97.5K | 0.02% | 315 |
|
|
2024
Q1 | $633K | Sell |
44,896
-45,121
| -50% | -$637K | 0.02% | 312 |
|
|
2023
Q4 | $940K | Sell |
90,017
-94,983
| -51% | -$992K | 0.03% | 272 |
|
|
2023
Q3 | $1.89M | Buy |
+185,000
| New | +$1.89M | 0.03% | 253 |
|
|
2018
Q3 | – | Sell |
-22,000
| Closed | -$535K | – | 309 |
|
|
2018
Q2 | $535K | Buy |
+22,000
| New | +$535K | 0.01% | 225 |
|
|
2017
Q4 | – | Sell |
-40,000
| Closed | -$704K | – | 350 |
|
|
2017
Q3 | $704K | Buy |
+40,000
| New | +$704K | 0.01% | 297 |
|